Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization.
Sign Up to like & getrecommendations! Published in 2019 at "Drug testing and analysis"
DOI: 10.1002/dta.2693
Abstract: Vascular Endothelial Growth Factor (VEGF) plays a crucial role in angiogenesis within solid cancers. Thus, targeting VEGF might be part of a feasible therapy for treating pathological neovascularization, and nanobodies - derived from Heavy chain-only… read more here.
Keywords: bivalent nanobody; nanobody; half life; vegf ... See more keywords